Candel Therapeutics (CADL) News Today $7.07 +0.11 (+1.58%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$7.00 -0.07 (-0.99%) As of 01/31/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Insider Stock Buying Of Candel Therapeutics Delivers Return On US$3.00m InvestmentJanuary 18, 2025 | finance.yahoo.comFrancesca Barone Sells 13,534 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) StockJanuary 18, 2025 | insidertrades.comFrancesca Barone Sells 13,534 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) StockCandel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) insider Francesca Barone sold 13,534 shares of the company's stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $7.22, for a total value of $97,715.48. Following the completion of the transaction, the insider now directly owns 110,673 shares in the company, valued at approximately $799,059.06. This represents a 10.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.January 17, 2025 | marketbeat.comSeshu Tyagarajan Sells 14,322 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) StockCandel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) CTO Seshu Tyagarajan sold 14,322 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $7.22, for a total value of $103,404.84. Following the completion of the sale, the chief technology officer now directly owns 96,790 shares of the company's stock, valued at $698,823.80. This represents a 12.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.January 17, 2025 | marketbeat.comCandel Therapeutics, Inc. (NASDAQ:CADL) Sees Significant Decline in Short InterestCandel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) was the target of a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 3,060,000 shares, a drop of 33.0% from the December 15th total of 4,570,000 shares. Currently, 11.1% of the company's stock are sold short. Based on an average daily trading volume, of 3,420,000 shares, the days-to-cover ratio is currently 0.9 days.January 15, 2025 | marketbeat.comCandel Therapeutics provides corporate update, highlights momentumJanuary 14, 2025 | markets.businessinsider.comCandel Therapeutics advancing lead candidate targeting prostate cancer towards FDA submissionJanuary 13, 2025 | proactiveinvestors.comCandel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025January 13, 2025 | globenewswire.comCandel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells $112,392.06 in StockJanuary 11, 2025 | insidertrades.comInsider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells 13,673 Shares of StockCandel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) insider Francesca Barone sold 13,673 shares of Candel Therapeutics stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $8.22, for a total transaction of $112,392.06. Following the sale, the insider now owns 124,207 shares in the company, valued at approximately $1,020,981.54. This represents a 9.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.January 10, 2025 | marketbeat.comShort Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Rises By 109.6%Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totalling 4,570,000 shares, a growth of 109.6% from the November 30th total of 2,180,000 shares. Based on an average trading volume of 3,200,000 shares, the days-to-cover ratio is presently 1.4 days. Approximately 17.4% of the shares of the company are sold short.December 27, 2024 | marketbeat.com2025 biotech outlook: Small-cap innovators tackling chronic and rare diseasesDecember 23, 2024 | proactiveinvestors.comFY2024 Earnings Forecast for CADL Issued By HC WainwrightCandel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Equities research analysts at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for shares of Candel Therapeutics in a report released on Wednesday, December 18th. HC Wainwright analyst V. Bernardino now expects that the cDecember 20, 2024 | marketbeat.comCandel Therapeutics rides high on promising Phase 3 data, funding boostDecember 19, 2024 | proactiveinvestors.comCandel Therapeutics, Inc. (NASDAQ:CADL) Director Paul B. Manning Acquires 1,250,000 SharesDecember 19, 2024 | insidertrades.comInsider Buying: Candel Therapeutics, Inc. (NASDAQ:CADL) Director Purchases 1,250,000 Shares of StockCandel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) Director Paul B. Manning acquired 1,250,000 shares of the company's stock in a transaction that occurred on Monday, December 16th. The shares were acquired at an average cost of $6.00 per share, for a total transaction of $7,500,000.00. Following the completion of the transaction, the director now directly owns 1,303,752 shares of the company's stock, valued at $7,822,512. The trade was a 2,325.49 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link.December 18, 2024 | marketbeat.comCandel Therapeutics' (CADL) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $19.00 price target (up previously from $11.00) on shares of Candel Therapeutics in a research report on Wednesday.December 18, 2024 | marketbeat.comCandel Therapeutics raises $92M in public offering following prostate cancer trial successDecember 16, 2024 | proactiveinvestors.comCandel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesDecember 16, 2024 | globenewswire.comCandel Therapeutics unveils $80M public offeringDecember 13, 2024 | proactiveinvestors.comCandel Therapeutics Prices Public Offering Of $80 Mln Of SharesDecember 13, 2024 | markets.businessinsider.comCandel Therapeutics slumps 28%, pricesDecember 13, 2024 | msn.comCandel Therapeutics Announces Pricing of Public OfferingDecember 12, 2024 | globenewswire.comCandel Therapeutics Announces $80 Million Proposed Public OfferingDecember 12, 2024 | globenewswire.comCandel Therapeutics Shares Are Up Today: What's Going On?December 12, 2024 | benzinga.comCandel Therapeutics Stock More Than Doubles After Strong Prostate Cancer Trial Results: Retail Goes WildDecember 11, 2024 | msn.comCandel Therapeutics Prostate Cancer Therapy Shows PromiseDecember 11, 2024 | finance.yahoo.comCandel stock rockets on Phase 3 results for CAN-2409 (update)December 11, 2024 | seekingalpha.comCandel Therapeutics: Surprising Win Puts Potential Drug Approval In SightDecember 11, 2024 | seekingalpha.comCandel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer DrugDecember 11, 2024 | investors.comCandel Therapeutics Shares Soar Premarket on Prostate Cancer StudyDecember 11, 2024 | marketwatch.comWhy Candel Therapeutics Is Rising In Pre-market?December 11, 2024 | markets.businessinsider.comWhy Candel Therapeutics Is Rising In Pre-market?December 11, 2024 | markets.businessinsider.comCandel Therapeutics reports positive Phase 3 results for CAN-2409 in localized prostate cancerDecember 11, 2024 | proactiveinvestors.comCandel Therapeutics' cancer drug meets late-stage trial goalsDecember 11, 2024 | reuters.comCandel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free SurvivalDecember 11, 2024 | globenewswire.comInsider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells 13,935 Shares of StockDecember 4, 2024 | insidertrades.comCandel Therapeutics is pushing for a paradigm shift in cancer treatmentNovember 29, 2024 | proactiveinvestors.comCandel Therapeutics CEO: Putting patients first is the key to reframing cancer treatmentNovember 22, 2024 | proactiveinvestors.comWhat is HC Wainwright's Forecast for CADL Q4 Earnings?Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Analysts at HC Wainwright issued their Q4 2024 earnings per share estimates for Candel Therapeutics in a report released on Monday, November 18th. HC Wainwright analyst V. Bernardino expects that the company will earn ($0.30) per share for tNovember 19, 2024 | marketbeat.comCandel Therapeutics Advances in Cancer Trials Amid Financial ChallengesNovember 19, 2024 | markets.businessinsider.comPromising Potential of Candel Therapeutics’ CAN-2409 Drives Buy RatingNovember 18, 2024 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for Candel Therapeutics (NASDAQ:CADL)HC Wainwright reiterated a "buy" rating and set a $11.00 price objective on shares of Candel Therapeutics in a research note on Monday.November 18, 2024 | marketbeat.comCandel Therapeutics, Inc. (NASDAQ:CADL) Short Interest UpdateCandel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) was the target of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 1,780,000 shares, an increase of 8.5% from the October 15th total of 1,640,000 shares. Approximately 9.0% of the company's stock are short sold. Based on an average daily volume of 255,200 shares, the short-interest ratio is presently 7.0 days.November 17, 2024 | marketbeat.comCandel Therapeutics reports Q3 EPS (33c) vs. (29c) last yearNovember 14, 2024 | markets.businessinsider.comCandel Therapeutics sees cash runway to end of 1Q25November 14, 2024 | markets.businessinsider.comCandel Therapeutics CEO anticipates 'paradigm shift' in prostate cancer treatment as Q3 work wraps upNovember 14, 2024 | proactiveinvestors.comCandel Therapeutics' CAN-3110 offers new hope for melanoma treatment – ICYMINovember 9, 2024 | proactiveinvestors.comCandel Therapeutics' CAN-3110 offers new hope for melanoma treatment – ICYMINovember 9, 2024 | proactiveinvestors.comCandel Therapeutics to Present at Jefferies London Healthcare Conference 2024November 8, 2024 | markets.businessinsider.com Get Candel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter. Email Address CADL Media Mentions By Week CADL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CADL News Sentiment▼1.870.69▲Average Medical News Sentiment CADL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CADL Articles This Week▼12▲CADL Articles Average Week Get Candel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NUVB News Today AVXL News Today CDMO News Today RLAY News Today TYRA News Today QURE News Today ORIC News Today SANA News Today CRMD News Today CRON News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CADL) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Candel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Candel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
